Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response

AIMS: To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed. M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zhang, Yingqiang, Fan, Wenzhe, Zhu, Kangshun, Lu, Ligong, Fu, Sirui, Huang, Jinhua, Wang, Yu, Yang, Jianyong, Huang, Yonghui, Yao, Wang, Li, Jiaping
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695205/
https://ncbi.nlm.nih.gov/pubmed/26093084
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky